Moderna, Inc. (NASDAQ:MRNA – Get Free Report) President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $112.99, for a total transaction of $1,694,850.00. Following the sale, the president now owns 1,574,187 shares of the company’s stock, valued at $177,867,389.13. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Stephen Hoge also recently made the following trade(s):
- On Tuesday, August 29th, Stephen Hoge sold 1,135 shares of Moderna stock. The stock was sold at an average price of $115.01, for a total transaction of $130,536.35.
- On Thursday, August 17th, Stephen Hoge sold 15,000 shares of Moderna stock. The stock was sold at an average price of $100.00, for a total transaction of $1,500,000.00.
- On Thursday, August 10th, Stephen Hoge sold 247 shares of Moderna stock. The stock was sold at an average price of $102.53, for a total value of $25,324.91.
- On Monday, July 17th, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $120.60, for a total value of $1,809,000.00.
Moderna Trading Down 9.1 %
Shares of MRNA stock opened at $104.14 on Tuesday. Moderna, Inc. has a 1 year low of $95.02 and a 1 year high of $217.25. The firm’s fifty day simple moving average is $112.49 and its 200 day simple moving average is $127.70. The firm has a market capitalization of $39.63 billion, a P/E ratio of 38.43 and a beta of 1.63. The company has a current ratio of 3.39, a quick ratio of 3.16 and a debt-to-equity ratio of 0.05.
Analyst Ratings Changes
MRNA has been the topic of several recent research reports. HSBC began coverage on shares of Moderna in a research report on Friday, July 14th. They set a “reduce” rating and a $97.00 price objective on the stock. UBS Group upgraded shares of Moderna from a “neutral” rating to a “buy” rating and cut their price target for the company from $221.00 to $191.00 in a report on Monday, June 26th. Morgan Stanley cut their price target on shares of Moderna from $128.00 to $123.00 and set an “equal weight” rating on the stock in a report on Friday, August 4th. Jefferies Financial Group cut their price target on shares of Moderna from $275.00 to $175.00 in a report on Friday, August 4th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Moderna from a “buy” rating to a “hold” rating and cut their price target for the company from $200.00 to $125.00 in a report on Thursday, August 3rd. Three analysts have rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $155.52.
Hedge Funds Weigh In On Moderna
Several large investors have recently added to or reduced their stakes in the company. ICA Group Wealth Management LLC bought a new position in shares of Moderna during the 4th quarter worth about $27,000. GHP Investment Advisors Inc. lifted its holdings in shares of Moderna by 208.3% during the 1st quarter. GHP Investment Advisors Inc. now owns 185 shares of the company’s stock worth $28,000 after acquiring an additional 125 shares during the period. Heritage Wealth Management LLC lifted its holdings in shares of Moderna by 100.0% during the 4th quarter. Heritage Wealth Management LLC now owns 226 shares of the company’s stock worth $41,000 after acquiring an additional 113 shares during the period. Stone House Investment Management LLC acquired a new stake in Moderna in the 1st quarter valued at $36,000. Finally, Close Asset Management Ltd boosted its stake in Moderna by 1,250.0% in the 2nd quarter. Close Asset Management Ltd now owns 270 shares of the company’s stock valued at $33,000 after buying an additional 250 shares in the last quarter. Institutional investors and hedge funds own 64.51% of the company’s stock.
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.
- Five stocks we like better than Moderna
- Crypto vs Stocks: How to Choose Your Investments
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- The How and Why of Investing in Large-Cap Stocks
- 5 Reasons Mullen Automotive is About to Turn a Corner
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.